Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Zai Lab Gains 5.65% to $19.65 as FDA Grants Second Fast Track Designation to DLL3-Targeting ADC

Zai Lab Limited (NASDAQ: ZLAB) added 5.65 per cent on Tuesday to close at $19.65, lifted by news that the FDA has extended a second Fast Track Designation to zocilurtatug pelitecan — known within the oncology community as zoci — for the treatment of …

Nitish Kishor | 11 May 2026

Exagen Surges 25% to $3.70 as Record Q1 Revenue and AVISE CTD Growth Reframe the Earnings Story

Exagen Inc. (NASDAQ: XGN) surged 25.42 per cent to $3.70 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnosticsBusinessat this stage of its commercial development: volume, pricing, and the trajectory …

Nitish Kishor | 11 May 2026

Actuate Therapeutics Falls 11.8% to $2.91 Despite FDA Clearing Phase 1/2 Trial for Oral Cancer Candidate

Actuate Therapeutics (NASDAQ: ACTU) suffered a sharpReversalon Tuesday, declining 11.82 per cent to $2.91, in what may rank as one of the more counterintuitive market reactions of the day. The company had just announced that the US Food and Drug Administration had cleared its …

Nitish Kishor | 11 May 2026

Longeveron Holds Near Flat at $0.8502 as FDA Strips ELPIS II of Pivotal Status Over Endpoint Concerns

Longeveron Inc. (NASDAQ: LGVN) barely moved on Tuesday, edging up just 0.59 per cent to $0.8502, in a muted market response to a regulatory development that, in a different sentiment environment, might have been expected to hit the stock considerably harder. The company disclosed …

Nitish Kishor | 11 May 2026